SG Americas Securities
ITRM

SG Americas Securities’s Iterum Therapeutics ITRM Stock Holding History

SG Americas Securities’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,464
Closed -$1K – 3521
2026
Q1 		$1K Buy
33,464
+20,682
+162% +$5.18K ﹤0.01% 3165
2025
Q4 		$4K Sell
12,782
-4,038
-24% -$2.18K ﹤0.01% 3547
2025
Q3 		$11K Buy
+16,820
New +$13.2K ﹤0.01% 3316

Other funds holding ITRM

Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
CCMW
Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

SG Americas Securities's ITRM Position: Q2 2026 in Review

SG Americas Securities sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 33,464 shares — an estimated $1K sold.

SG Americas Securities first reported a position in ITRM in Q3 2025 and held it in 3 quarters. The position peaked at $11K in Q3 2025. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.

  • SG Americas Securities reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SG Americas Securities sold 33,464 Iterum Therapeutics shares in Q2 2026, an estimated $1K.
  • SG Americas Securities first reported a position in Iterum Therapeutics in Q3 2025 and held it in 3 quarters.
  • SG Americas Securities's Iterum Therapeutics position peaked at $11K in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.